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Veith et al. (2009) analyzed over 17,000 compounds for interaction with the five major human cytochrome
P450 drug-metabolizing enzymes. Analysis of the results provides some structural insight and framework
for expansion.CytochromeP450 (P450 orCYP) enzymes
are involved in approximately three
fourths of the reactions of drug metabo-
lism in humans, and five liver P450s (1A2,
2C9, 2C19, 2D6, 3A4) account for greater
than 90% of these reactions (Guengerich,
2005). Many drug-drug interactions and
drug side effects can be attributed to
variations in these P450s and to the inter-
action of drugs with the P450s (e.g., inhib-
iting metabolism of each other via com-
petitive or irreversible interactions). In
silico prediction of P450 liganding would
be desirable, but even with P450 crystal
structures available, the malleability of
many of the P450s has confounded
docking predictions. Collectively these
five P450s probably have millions of
substrates and inhibitors, if one considers
all of the potential natural and synthetic
substrates. Oxidation of drugs by the
high-valent iron chemistry of P450 (the
‘‘blowtorch’’) seems to be largely a func-
tion of getting a particular atom of a mole-
cule into the right place in the active site
(Ortiz de Montellano and De Voss, 2005).
Many drug candidates are discarded
because metabolism is too fast, and
some drugs are almost completely resis-
tant to oxidation for unknown reasons
(e.g., rosuvastatin, varenicline).
Veith et al. (2009) screened libraries
containing a total of 17,193 compounds
for the inhibition of activity of these five
P450s using high-throughput lumines-
cence assays developed by Promega.
Although the term ‘‘activity’’ was used
here, the authors really mean inhibition,
although (as pointed out by the authors)
the results do not discriminate between
a test compound being a substrate or an
inhibitor. With regard to the title, the indi-
vidual P450 enzymes are not ‘‘isozymes,’’
in the sense that they do not necessarilycatalyze the same reaction. The results,
obtained by varying concentrations of
each test compound, were compiled and
used to propose some structure-activity
relationships.
Although information of this type has
been accumulated in some pharmaceu-
tical companies (Afzelius et al., 2007)
this effort of Veith et al. (2009) appears
to be the largest public effort of this type
to date. Several interesting features have
come out of the analysis. The authors
found that the U.S. Food andDrug Admin-
istration (FDA)-approved drugs within
the set showed less P450 inhibition
than did the rest of the library, which is
logical because modern screening strate-
gies should discriminate against strong
P450 inhibitors. An interesting point is
that a substantial fraction of the com-
pounds tested (5%–10%) had IC50 values
< 1 mM, which has been a rough guide for
potential concern in some companies.
Another interesting result is that 350 of
the 17,143 compounds (2%) inhibited
all five P450s. The authors state that
amines were overrepresented in such
‘‘pan-activity.’’ In Figure 4 of Veith et al.
(2009), the analysis shows an overrepre-
sentation of thiophenes and methylene-
dioxyphenyl moieties in the inhibition of
all P450s, which may not be surprising in
light of the known tendencies of these
two classes of compounds to be oxidized
to reactive products (Nelson, 1982; Guen-
gerich and MacDonald, 2007). Indoles, in
this class, are often substrates for P450s
(Gillam et al., 2000), as are naphthalenes.
The inclusion of pyrimidines as pan-active
is a surprise, in light of general knowledge
of drug metabolism. What is missing
from the analysis (and may not be
feasible) is a definition of patterns of inhi-
bition, regarding where in a large mole-Chemistry & Biology 16, December 24, 2009 ªcule a particular group is positioned.
One group of compounds that was not
reported for pan-activity was azoles,
which have been historically recognized
as P450 inhibitors due to heme liganding
(and have even been used as drugs to
block some P450s, such as yeast P450
51A1).
One of the intriguing areas of interest in
the P450 field is the stimulation of some
reactions by ligands, which still defies
mechanistic explanation. Such stimula-
tion was reported for 3% of the com-
pounds with P450s 2C9, 2C19, and 3A4.
The in vivo relevance of this phenomenon
in humans is still a matter of speculation.
One limitation of this work is that the
results were collected using only the lumi-
nescence-generating substrates, which
the authors acknowledge. These (and
fluorescence assays) have lost some
favor in the pharmaceutical industry in
screening assays in recent years. How-
ever, the authors do a reasonable job of
correlating their results with standardized
P450 assays, in subsets of the library.
Veith et al. (2009) do not distinguish
between P450 substrates and inhibitors,
as the authors acknowledge. That is,
a P450 substrate would also be an inhib-
itor in this assay (Figure 1). It is also pos-
sible that a substrate might be oxidized
to attenuate inhibition in the assay (Shi-
mada et al., 2008). Another limitation of
the work, acknowledged by the authors,
is that this screen is not designed to iden-
tify mechanism-based inhibitors (also
called time-dependent or suicide inhibi-
tors), which are fairly common (particu-
larly with P450 3A4) and more problem-
atic than simple competitive inhibitors.
In principle, these should show up in the
primary screen because they are also
necessarily competitive inhibitors and2009 Elsevier Ltd All rights reserved 1215
Figure 1. Outcomes of Interaction of a Ligand with a P450
The interaction of a compound with a P450 (P450 3A4 structure is shown, pdb
code 1TQN) can be related to the chemical being a substrate, inhibitor, irre-
versible inhibitor, or stimulator—or combinations thereof. Also note that
many P450 ligands can interact via multiple bindingmodes, leading to multiple
products in the case of substrates (Guengerich, 2005).
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pre-incubation settings (Sil-
verman, 1995).
The results of Veith et al.
(2009) can be used to predict
inhibition by drug candidates,
but a number of other factors
are involved (Food and Drug
Administration, 2006) and
ultimately the true test for
inhibition is an in vivo human
experiment. The results can
also be used to predict if
compounds are substrates,
and the methods for following
these up are relatively
straightforward. Finally, the
information, if available, couldbe coupled with similar screens of other
libraries—perhaps even if run on different
platforms—to expand the results. The
database used in this analysis is available
in the online supplemental information.
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Cegelski et al. (2009) demonstrate the importance of amyloid production for biofilm formation and host colo-
nization using several mutant strains of pathogenic E. coli and small molecule inhibitors. This work reveals
a path forward for studying the role of bacterial amyloids in vivo and suggests the potential for small mole-
cules to target multiple biofilm formation pathways.The increased prevalence of antibiotic
resistant bacteria heralds a need for new
drugs and novel strategies for identifying
better drug targets. One such strategy
is to target microbial virulence factors,
which are important for causing pathology
but are not required for the microbe to
survive in vitro. This strategy avoids tar-
geting essential gene functions, which
may result in strong evolutionary selectionfor resistant strains. While this idea
remains theoretical, efforts have been
increased to develop new antibiotics
based on this principle. One virulence
process of particular interest to target is
biofilm formation because of the associ-
ated antibiotic insensitivity of bacteria
surviving within biofilms. Cegelski et al.
(2009) have recently generated tools to
allow researchers to address the relativeimportance of different bacterial attach-
ment strategies during biofilm formation
in vivo in amodel for urinary tract infection.
Many pathogenic bacteria elaborate
virulence factors in order to cause dis-
ease. Examples of factors include secre-
tion systems to inject effector molecules
into host cells, secreted toxins thatmanip-
ulate host cell processes or outright kill
host cells, quorum-sensing systems that
